<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438957</url>
  </required_header>
  <id_info>
    <org_study_id>DEX-303</org_study_id>
    <nct_id>NCT01438957</nct_id>
  </id_info>
  <brief_title>Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation</brief_title>
  <official_title>Phase III Randomized Placebo-controlled Double Blind Comparative Study to Investigate the Efficacy and Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation Under Monitored Sedation Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maruishi Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospira, now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy and safety of DA-9501 (Dexmedetomidine)
      in patients who require sedation during the surgery that requires epidural or spinal
      anesthesia without intubation under monitored sedation care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III, randomized, placebo controlled, double blind, parallel comparative study
      (Therapeutic confirmatory trial), to evaluate the efficacy and the safety of Dexmedetomidine
      in non-intubated patients who require sedation during surgery with spinal or epidural
      anesthesia under monitored sedation care
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of patients who did not require rescue administration of propofol to achieve and maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 during the study drug administration.</measure>
    <time_frame>Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Administration frequency and dosage of propofol required to achieve and maintain OAA/S score ≤4 during the study drug administration</measure>
    <time_frame>15 minutes after the start of study drug, if the OAA/S score is 5.</time_frame>
    <description>If the OAA/S score is 5, 0.2 mg/kg of propofol as a sedative is administered intravenously by slow &quot;IV push&quot; and the administration is to be repeated until the target level of sedation (OAA/S score ≤4) is achieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first rescue administration of propofol</measure>
    <time_frame>During the study drug infusion period (≥15 minutes [Approximate])</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of patients who did not require rescue administration of fentanyl during the study drug administration</measure>
    <time_frame>After the surgery start, the administration of fentanyl is permissible as required to treat pain. In case of repeated dose, the dosing interval should be ≥15 minutes.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time spent OAA/S Score ≤4 during the study drug infusion</measure>
    <time_frame>Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time spent OAA/S Score 3 to 4 during the study drug infusion</measure>
    <time_frame>Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to attain the point where patient is recovered assessed by Aldrete score following discontinuation of the study drug infusion</measure>
    <time_frame>Every 15 ± 2 minutes until the score of each item becomes ≥1 and the total value becomes ≥8.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) score evaluation by Investigator or sub-investigator (ease of maintaining sedation level, hemodynamic stability, respiratory stability, subject's cooperativeness)</measure>
    <time_frame>Within 24 hours after completion of the study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score evaluation of satisfaction and anxiety of the subject</measure>
    <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dexmedetomidine 0 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0 mcg/kg/hr Maintenance dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.067 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 0.4 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.25 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 1.5 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.5 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 3 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 1.0 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 6 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine hydrochloride</intervention_name>
    <description>Dexmedetomidine 0.2 to 0.7 mcg/kg/hr</description>
    <arm_group_label>Dexmedetomidine 0.067 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.25 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.5 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 1.0 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has signed and dated the Informed Consent after the study had been fully
             explained.

          2. Patient is male or female, at least 20 years of age when the Informed Consent is
             obtained.

          3. American Society for Anesthesiologists (ASA) I to III Class.

          4. Patient who requires sedation during the elective surgery which requires ≥30mins
             (expected time) without intubation under monitored sedation care.

          5. Patient undergoing a surgery requiring epidural or spinal anesthesia

        Exclusion Criteria:

          1. Patient who underwent general anesthesia within 7 days, or who received other study
             drugs within 30 days from the date of consent.

          2. Patient with &lt;92% SpO2, at the physical examination prior to the study drug
             administration, or ventilatory failure which requires intubation or Laryngeal Mask.

          3. Patient with central nervous system pathology which may lead to increased intracranial
             pressure, uncontrolled seizures, psychiatric disorder which may be confused with the
             response to sedation treatment.

          4. Patient who require general anesthesia.

          5. Patient who receives treatment by alpha-2 agonists or alpha-2 antagonists within seven
             days of scheduled surgery or procedure.

          6. Patient in whom opioids, DA-9501 or other alpha-2 agonists, or drugs which may be used
             in the study are contraindicated.

          7. Patient diagnosed with unstable angina or acute myocardiac infarction within 6 weeks
             from the date of consent.

          8. Patient whose heart rate is &lt;60 bpm, systolic blood pressure is &lt;90 mmHg by the
             physical examination prior to the study drug administration.

          9. Patient has third degree heart block, unless the patient has a pacemaker or transverse
             pacing wires are in place.

         10. Patient who has experienced an increase in alanine transaminase (ALT) and / or
             aspartate aminotransferase (AST) more than double the upper normal limit within 2
             months of the date of consent, or who has a history of liver insufficiency.

         11. Pregnant or lactating woman.

         12. In the Investigator's or subinvestigator's opinion, the patient has any symptom or
             condition which might increase risk to the patient by conducting the study or preclude
             obtaining satisfactory study data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asahikawa Medical University Hospital</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kochi Medical School Hospital</name>
      <address>
        <city>Nangoku</city>
        <state>Kochi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinshul University Hospital</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimane University Hospital</name>
      <address>
        <city>Izumo</city>
        <state>Shimane</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Yonago</city>
        <state>Tottori</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Kyoto Daini Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miyazaki Hospital</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitano Hospital, The Tazuke Kofukai Medical Research Institute</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>September 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2011</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Sedation</keyword>
  <keyword>Non-intubation</keyword>
  <keyword>epidural anesthesia</keyword>
  <keyword>spinal anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

